Skip to main navigation
Ventyx Biosciences, Inc. Ventyx Biosciences, Inc.
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Advisory Board
    • Contact
  • Science
  • Pipeline
    • Overview
    • VTX958
    • VTX002
    • VTX2735
    • VTX3232
  • Investors
    • Overview
    • News & events
    • Stock information
    • Governance
    • Financials & filings
    • IR resources
  • Careers
  • News Releases
  • Events
  • Presentations

News Releases

News Releases

December 1, 2022
Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis
Read more
November 22, 2022
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Read more
November 3, 2022
Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Read more
October 27, 2022
Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022
Read more
October 27, 2022
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Read more
September 19, 2022
Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock
Read more
August 29, 2022
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Read more
August 15, 2022
Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Read more
August 15, 2022
Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958
Read more
August 11, 2022
Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022
Read more
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Next page ›
  • Last page »
Displaying 11 - 20 of 33


Email Alerts


FAQ


Contact IR


RSS Feeds
Contact us
info@ventyxbio.com
  • Privacy Policy
  • Terms Of Use
© 2023 Ventyx Biosciences, Inc. All rights reserved.
linkedin
Ventyx Biosciences, Inc.